Insider trade

Director sold ~$593K of KRYS shares in the open market

Traded Mar 4, 2026 · Filed Mar 6, 2026

Why it stands out

A Krystal Biotech director sold $593K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$592,535

Shares × reported transaction price

Timing vs results

15 days after results of Feb 17, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−3.3%	−1.4%	−1.9%
30 days	+2.1%	−0.3%	+2.5%
90 days	+16.7%	+9.0%	+7.7%
180 days	+35.8%	+12.9%	+22.9%

Past results only. Not a forecast.

The transaction was executed in multiple trades ranging from $263 to $263.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Scheduled in advanceFiled 7mo ago

Automatic saleFiled 7mo ago

Automatic saleFiled 7mo ago